
Cancer centers rush to enroll patients in Revolution Medicines' pancreatic cancer drug after positive trial results.
Revolution Medicines received FDA approval for an expanded access program for its pancreatic cancer drug, daraxonrasib, following positive Phase 3 trial results showing significant survival benefits. The drug demonstrated a median overall survival of...

